Comparing standard interferon and interferon conjugated with polyethylene glycol for treatment of patients chronically infected with hepatitis B virus infection

The efficacy of interferon (IFN) has recently improved by the replacement of standard IFN by the type conjugated with polyethylene glycol IFN (PEG IFN). However, the superiority of PEG IFN regimen to therapy with standard IFN remains uncertain.
The present study aimed to assess and compare the efficacy of the two standard IFN and PEG IFN regimens for the treatment of patients chronically infected with hepatitis B virus (HBV) infection.
The present study was conducted as a retrospective, cohort study assessing 138 consecutive patients diagnosed as a case infected chronically with HBV. The patients were randomly assigned to receive standard IFN regimen (n = 71) intravenously or PEG IFN regimen (n = 67) intravenously for total 24 weeks. All patients were monitored monthly regarding serum aminotransferase level and hepatitis B e antigen (HBe-Ag) positivity as the viral load.
Overall, 8.4% in standard IFN group and 10.4% in PEG IFN responded to the treatment regimens with no between-group difference (P = 0.715). The response to treatment protocols was independent to gender, age, and viral load. In addition, 66.7% responded to standard IFN regimen, and 42.9% responded to PEG IFN regimen were positive for HBe-Ag with no difference between the two protocols (P = 0.639). Adjusted for HBe-Ag positivity, the type of IFN used for the treatment of chronic hepatitis B infection could not be effective factor (odds ratio = 0.792, P = 0.690).
Our study could not demonstrate the superiority of PEG IFN to standard IFN for treating chronic HBV infection.